Robert A. Copeland, President of Research and CSO at Epizyme, Inc. (EPZM), sold 1,682 shares at $13.82 ($23K) on 2015-12-07, disclosed to the SEC on 2015-12-08.
Scheduled sale ($23k) by President of Research and CSO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| EPZM | SELL | 2017-04-05 | $41K | — | Filing → |
| EPZM | SELL | 2016-08-03 | $83K | — | Filing → |
| EPZM | SELL | 2016-07-07 | $80K | — | Filing → |